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Abstract
Gigantoxin I, isolated from sea anemone Stichodactyla gigantea, was previously described as the first epidermal growth
factor (EGF)-like toxin from natural origin. In this study, we discovered the interaction between the transient receptor
potential vanilloid subtype I (TRPV1) channels and gigantoxin I. The TRPV1 channel is a non-selective cation channel
involved in pain sensation and is described as pharmacological target of cnidaria venom. Our results highlight the invol-
vement of the epidermal growth factor receptor/phospholipaseA2/arachidonic acid/lipoxygenase (EGFR/PLA2/AA/
LOX) pathway in the indirect activation of TRPV1 channels by gigantoxin I. This is the first time that this pathway is
described in the indirect activation of TRPV1 channels by toxins. This knowledge not only gives insights into the pos-
sible induced effects by this new group of toxins, but also leads to a better understanding of the regulatory mechanism
of TRPV1 channels themselves.
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1. Introduction
The phylum of Cnidaria represents exclusively
aquatic animals such as sea anemones and jellyfish. With
more than 7600 species, the Cnidaria is one of the largest
phyla of marine animals. According to their morphologi-
cal characters, the cnidarians are divided into 4 classes:
the Anthozoa (meaning “flower animals”) including co-
rals and sea anemones, the Hydrozoa (meaning “water
animals”) which include for example the Portuguese man-
of-war and fire corals, the Cubozoa (“cube animals”)
which include the box jellyfish and the Scyphozoa (mea-
ning “bowl animals”) which include the jellyfish. The na-
me Cnidaria comes from the Greek word “cnidos” which
means stinging nettle. Despite the fact that they are incre-
dibly diverse in form, they are united because of their stin-
ging cells called nematocysts. These stinging cells are
used to capture and subdue the prey. The nematocyst is a
coiled thread-like stinger. When the nematocyst is called
upon to fire, the thread is uncoiled, and springs straight.
The harpoon-like thread punctures through the cnidocyte
wall into the prey. Most cnidarians have a toxin in their
stinger that helps to immobilize the prey. The nematocyst
is fired either by the tentacle touching prey or in some ca-
ses by a nerve impulse from the animal telling it to fire.1
Most cnidarian nematocysts are not harmful to humans, as
the stinger cannot penetrate sufficiently into human skin
to inflict any harm. There are some jellyfish, however,
which can deliver extremely painful and, in a few cases,
even fatal stings to humans.
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Sea anemones are a rich source of protein and pep-
tide toxins which are generally divided into three classes:
hemolysins (15–21 kDa),2–5 sodium channel toxins (3–5
kDa)6–9 and potassium channel toxins (3.5–6.5 kDa).10–14
However, Shiomi and Honma isolated gigantoxin I, a
peptide toxin from Stichodactyla gigantea that has 33%
homologies with mammalian epidermal growth factor
(EGF)15 (Figure 1). In accordance with these sequence
homologies, including the location of the six cysteine re-
sidues, this toxin exhibits EGF activity as rounding of hu-
man epidermoid carcinoma A431 cells. Herein, a redistri-
bution of PLC-γ1 to the plasma membrane area, in parti-
cular newly formed ruffles accompanied by increased ac-
tin polymerization, was observed.16 Also tyrosine phosp-
horylation of the EGF receptor was described.15 Intere-
stingly, gigantoxin I is weakly lethal but potently paraly-
tic to crabs. In spite of these known biological activities,
the pharmacological target(s) of this toxin remain(s) unc-
lear. In this study, we investigated the effect of gigantoxin
I on the Transient Receptor Potential Vanilloid subtype 1
(TRPV1) channel that was previously described as phar-
macological target of cnidaria (e.g. sea anemone) venoms
and polycyclic ether toxins.17–18 Only recently, the first
sea anemone peptide, APHC1, isolated from Heteractis
crispa, with analgesic and antagonistic activity on TR-
PV1 channels has been reported.19 Unfortunately, no mo-
lecular action working mechanism has been put forward
and it is currently not known if APHC1 interacts directly
or indirectly with TRPV1 channels. It is only very re-
cently that the first action mechanism of a toxin activa-
ting TRPV1 channels was revealed, showing that the ou-
ter pore domain is the targeting mechanism of a bivalent
tarantula toxin.20
Transient receptor potential (TRP) channels consti-
tute a superfamily of cation permeable channels. The
founding member of this family was identified as a Dro-
sophila gene product required for visual transduction.21
Spontaneous mutations in the TRP-gene lead to TRP-defi-
cient flies which are blinded by intense light.22 This is
caused by a disruption of subsequent Ca2+-dependent
adaptation and thus leads to a sustained Ca2+ entry via
TRP ion channels. The name “transient receptor poten-
tial” is based on the transient (normal) rather than sustai-
ned (mutation) response to light of the flies carrying a mu-
tant in the trp locus. Further studies on the Drosophila me-
lanogaster phototransduction indicated that TRP is the
target of a phosphoinositide cascade. This leads to the
suggestion that phototransduction in Drosophila might be
analogous to the general and widespread process of
phosphoinositide-mediated Ca2+ influx in other cells.23
The TRPV1 channel, a ligand-gated and non-selecti-
ve cation channel that is expressed in peripheral sensory
neurons, is one of the key players in peripheral pain sensa-
tion (for an overview of its function and expression profi-
Figure 1. Sequence homology between gigantoxin I and EGF factors
Table 1. Overview of the function and expression profiles of TRPV channels (PCa, permeability for Ca ions; PNa, permeability for Na ions; TG, tri-
geminal ganglia; DRG, dorsal root ganglia).
gene name PCa/PNa proposed functions / possible disease connections highest expression
TRPV subfamily
TRPV1 3.8 (heat), detection of mild noxious heat, taste/ TG, DRG neurons, urinary 
9.6 (vanilloids) functional bowel disease, inflammatory bowel disease, bladder, testis, brain, 
ostheoarthritis, pancreatitis, impaired bladder contractions, respiratory tract, 
impaired thermal hyperalgesia, asthma, cystitis, gastrointestinal tract
schizophrenia, gastroesophagal reflux 
TRPV2 3 sensing thermal pain, mechanosensing/ DRG, spinal cord, brain, 
role in cardiomyopathy, cardiac hypertrophy, interstitial spleen, intestine
fibrosis, muscular dystrophia, prostate cancer
TRPV3 2.6 warm sensing, osmosensing/defective environmental TG, DRG, spinal cord, 
thermosensation, hairlessness, atopic dermatitis, breast brain, keratinocytes, tongue
cancer, non-isulin-dependent diabetes mellitus
TRPV4 6 osmosensing, warm sensing, nociception, pressure sensing/ DRG, kidney, lung, spleen, 
hypotonic hyperalgesia, impaired acidic nociception, testis, heart, liver, 
impaired thermal hyperalgesia, asthma, neuropathic pain, keratinocytes, endothelia
hypertension, cardiopathy
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le, refer to Table 1). TRPV1 is heat and acid sensitive and
can be activated by pungent substances like capsaicin.
Although capsaicin had been already known since ancient
times to have an analgesic effect, the channel was only
discovered in 1997 as the physiological target of capsai-
cin. Despite the fact that numerous analgesics are already
on the market, pain treatment remains one of the major
problems in the medical world. Therefore, the search for
new and more effective analgesics is still going on. The
discovery of TRPV1 channels started a new chapter in the
research to novel generation analgesics. In order to pre-
vent side effects, it is very important to know the mecha-
nisms and pathways involved in TRPV1 channel functio-
ning. Therefore, basic pharmacological research is indis-
pensable.
Members of the TRP channel superfamily share
the common structural features of six transmembrane
segments (TM) which cross the cell membrane, a pore
forming hydrophobic loop between the fifth and the
sixth segment and both cytosolic carboxy- and amino-
termini (Figure 2). Although this basic topology is com-
mon to many ion channel families, such as voltage-ga-
ted potassium channels, TRP and voltage-gated potas-
sium channels show relatively little sequence homology.
A likely common feature between voltage-gated potas-
sium channels and TRP channels is their tetrameric
structure. Recently, the 19 Å structure of TRPV1 chan-
nels was partly revealed by using electrocryomicros-
copy.24 It exhibits fourfold symmetry and comprises two
distinct regions: a large open basket-like domain, likely
corresponding to the cytoplasmic N- and C-terminal
portions, and a more compact domain, corresponding to
the transmembrane portion. Remarkably, a similar two-
domain arrangement referred to as a “hanging gondola”
has been observed in 3D structures of Kv1.2 channel. In
general, this structure follows the basic structural orga-
nisation described above.
The TRPV1 channel is known as the heat transducer
in sensory neurons because the channel is activated at a
temperature above 42 °C. Well-known direct activators
are capsaicin, the pungent substance found in hot chilli
peppers, and protons. In vivo and in vitro studies reveal
that inflammatory mediators like bradykinin, prostaglan-
dine E2 (PGE2), extracellular ATP, glutamate and nerve
growth factor can indirectly sensitize TRPV1 chan-
nels.25–27 This is possible via various mechanisms such as
increasing TRPV1 channel expression levels in the mem-
brane,28–29 inducing TRPV1 channel phosphorylation by
protein kinases30–31 or releasing channel inhibition by
phosphatidylinositol 4,5-biphosphate (PIP2) and thus sen-
sitizing the channel for agonist stimulation.30–32 In addi-
tion, these inflammatory mediators act on G-protein cou-
pled receptors (GPCRs) or, in case of nerve growth factor,
on tyrosine kinase pathways. These can induce on their
turn, via activation of phospholipase C (PLC) and/or
phospholipase A2 (PLA2), the release of arachidonic acid
(AA) and lipoxygenase products of arachidonic acid (e.g.
hydroperoxyeicosatetraenoic acid or HPETE), substances
which are known as TRPV1 channel agonists.33–34 Finally,
the endogenous ligand anandamide has also been shown
to activate TRPV1 channels.35
In our work presented here, we have set out to eluci-
date the pharmacological mechanism of the molecular in-
teraction between the sea anemone peptide gigantoxin I
and TRPV1 channels, and have investigated several regu-
lating and activating pathways of TRPV1 channels. It is
concluded that the interaction between the toxin and TR-
PV1 channels is PLA2 pathway dependent.
2. Materials and Methods
2. 1. Isolation of Gigantoxin I and 
Determination of Amino Acid Sequence
The isolation and amino acid determination of gi-
gantoxin I was described previously by Shiomi and Hon-
ma.15
Figure 2. Basic architecture of TRP (TRPV1) channels. Tetrameric structure of the functional channel exists of four domains. One domain has six
transmembrane segments and a pore forming hydrophobic loop between the fifth and the sixth segment. Ankyrin-binding domains (A) can be found
in the N-terminus.
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2. 2. Molecular Biology
cRNA transcripts were synthesized from XbaI-li-
nearized VR1 cDNA templates using T7 RNA polymerase
(Ambion).
Mutant S502A/S800A was made using Quick Chan-
ge II site-directed mutagenesis kit (Stratagene). In a first
step, mutant S502A was made using primers 5’-
G G G G A C TAT T T C C G A G G C A C C G G A G A -
GATCTTGTC-3’ and 5’-GACAAGATCTCTCCGGTG
CCTCGGAAATAGTCCCC-3’. Cycling parameters were
set according to the manufacturer’s guidelines. The mu-
tated cDNA was transformed into XL-1 blue cells and c-
DNA was isolated using Wizard Miniprep kit (Promega).
The construct was checked by cDNA sequencing. In a
second step, mutant S800A was made starting from the
S502A mutant cDNA. The following primers were
used; 5’-CGTCAAGCGCACCCTGGCCTTCTCCCT
GAGGTCAG-3’ and 5’-CTGACCTCAGGGAGAAG
GCCAGGGTGCGCTTGACG-3’. RNA was synthesi-
zed from the linearized plasmid using T7 mMessage m-
Machine transcription kit. A second cDNA sequencing
confirmed the sequence of the full S502A/S800A con-
struct.
Concentration of cRNA was determined by measu-
ring the absorbance at 230, 260 and 280 nm.
2. 3. Expression in Xenopus Oocytes 
and Electrophysiology
Oocytes were harvested from anaesthetized female
Xenopus laevis frogs as previously described36 and were
injected with 0.5–5 ng TRPV1 cRNA. Oocytes were in-
cubated in ND96 solution supplemented with 50 mg/L
gentamycin. Two to seven days after injection, two-elec-
trode voltage-clamp recording was performed. Currents
were measured in ND96 solution at a holding potential
of –90 mV during 400 s. The recording chamber was
perfused at a rate of 2 mL min–1 with a ND-96 solution
containing (in mM) 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2,
5 HEPES (pH 7.4). Temperature of the perfusate was
kept at 22 °C and controlled using a SC-20 dual in-line
heater/cooler (Warner Instruments) and pH was kept at
7.4. As previously described,37 capsaicin (2 μM) was
used as an agonist and capsazepine (10 μM) as an anta-
gonist of TRPV1 channels. Capsaicin, capsazepine,
Kt5720, U-73122, wortmannin and 5,8,11,14-eicosate-
traynoic acid (ETYA) were all purchased from Sigma
and dissolved in DMSO. The final dilution in ND96,
used as test or incubation solution, contained maximal
0.5% DMSO. Oocytes were incubated for at least 30 mi-
nutes in Kt5720, U-73122, wortmannin or ETYA before
measurements were done. All experiments were carried
out on at least 3 different oocytes. Gigantoxin I was dis-
solved in ND96 and administered using the described
perfusion system.
3. Results
Administration of 1.5 μM and 3 μM gigantoxin I on
wild type TRPV1 channels induced no visible effect (n =
3) (Figure 3A). In contrast, when the toxin (1 μM) was ad-
ministrated in the presence of capsaicin (2 μM), an activa-
tor of TRPV1 channels, an extra inward current was dis-
cernible (n = 10) (Figure 3B). A similar phenomenon has
been observed with cnidaria venom and polycyclic ether
toxins and was defined as positive allosterism.17–18
Figure 3. a) Example of TRPV1 current induced by application of
2 μM capsaicin (CAP). No current is visible after application of 1.5
and 3 μM gigantoxin I (GIGANTx). Capsazepine is used as a
TRPV1 channel blocker. b) Example of the extra inward current vi-
sible when 1 μM GIGANTx is added together with CAP (2 μM). In
(A) and (B), capsazepine (CZP, 10 μM) was used as a TRPV1 chan-
nel blocker.
a)
b)
In order to elucidate the mechanism behind this allo-
steric effect, regulatory factors of TRPV1 channels which
might be involved in this effect were investigated step by
step (Figure 4). The first factor we excluded was protein
kinase C (PKC). This factor is known to sensitize the
channel by phosphorylation on two serine residues (Ser-
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502 and Ser-800). A TRPV1 channel mutant was made re-
placing both serine residues into alanines (S502A/S800A
mutant). This mutant has already been described and is
generally accepted as research tool in the involvement of
PKC in the effect of substances on TRPV1 channels.38
Tests of gigantoxin I on this mutated channel showed the
same allosteric effect of the toxin when administered to-
gether with capsaicin (n = 4), indicating that PKC induced
phosphorylation is not the main working mechanism. The
second intracellular regulator we checked was protein ki-
nase A (PKA). Because four phosphorylation sites on the
TRPV1 channel are known for PKA (serine-116, threoni-
ne-144, threonine-370 and serine-502), we have chosen to
use the potent and selective PKA inhibitor, Kt5720. This
pharmacological tool is widely used when investigating
the role of PKA in the modulation of ion channels.39 Con-
trol tests were carried out in order to check the activity of
Kt5720. Indeed, the capsaicin induced current after 30
min incubation in Kt5720 (3 μM) was significantly de-
creased, indicating that the PKA dependent recovery from
desensitization was prevented (data not shown).40 Measu-
rements on Kt5720 incubated oocytes showed the same
allosteric effect of the toxin together with capsaicin (n =
3), indicating that PKA is most probably not involved in
the toxin effect. A third factor that might be involved in
the described action of gigantoxin I is PIP2. It has been
shown that mutations that weaken the TRPV1-PIP2 inte-
raction induce a reduction of thresholds for chemical and
physical stimuli.41 Therefore, it can be postulated that gi-
gantoxin I reduces the threshold to capsaicin by promo-
ting the hydrolysis of PIP2 by phospholypase C (PLC) in-
to diacylglycerol (DAG) and inositol (1,4,5)-triphosphate
(IP3). As a consequence, more TRPV1 channels will be
activated by the same capsaicin concentration, leading to
a greater inward current. In order to test this hypothesis, 3
μM U-73122, a PLC and PLA2 inhibitor, was added to the
incubation solution as described before.42–43 Control expe-
riments were carried out. Herein, desensitization of 
TRPV1 channels to capsaicin was clearly inhibited by U-
73122 (data not shown).When gigantoxin I was tested on
Figure 4. The involvement of different intracellular pathways in the gigantoxin I induced effect on TRPV1 channel is checked. Numbers indicated
in the pathway figures refer to tests excluding specific pathways. The corresponding currents are shown.
1. Gigantoxin I effect is tested on S502A/S800A mutants in order to check the involvement of PLC. The allosteric effect is still visible, indicating
no mayor involvement of this pathway. 2. Kt5720 is used as PKA inhibitor. Current show visible effect of the toxin, indicating no mayor effect of
PKA in the induction of the gigantoxin I effect. 3. U-73122, used as non-specific PLC and PLA2 inhibitor, blocked the allosteric effect of giganto-
xin I. 4. Wortmannin incubation, leading to a higher PIP2 concentration via the block of PI3K, does not influence the gigantoxin I effect on TRPV1
channels. 5. ETYA, a non-specific COX and LOX inhibitor, blocked the allosteric effect. The pathway that appears to be involved in the described
effect is indicated with black arrows.
TRPV1, transient receptor vanilloid subtype 1; CAP, capsaicin; CZP, capsazepin; PIP3, phosphatidylinositol triphospate; AC, adenylate cyclase;
GIGANTx, gigantoxin I; EGFR, epidermal growth factor receptor; GPCR, G-protein coupled receptor; PLA2, phospholipase A2; AA, arachidonic
acid; COX, cyclooxygenase; LOX, lipoxygenase; PIP2, phosphatidylinositol biphosphate; HPETE, hydroperoxyeicosatetraenoic acid; PKC, pro-
tein kinase C; PKA, protein kinase A; PLC, phospholipase C; DAG, diacylglycerol; IP3, inositol (1,4,5)-triphosphate; PGE2, Prostaglandine E2.
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the incubated oocytes, no further effect was visible (n =
5). This test leaves two open possibilities: the toxin de-
creases the PIP2 concentration or PLA2 is involved in the
induction of the effect. Therefore, wortmannin (100 μM),
an inhibitor of phosphoinositide 3-kinases (PI3K) was ad-
ded to the incubation solution. PI3K phosphorylates PIP2
into PIP3 and thus decreases the PIP2 concentration. In-
deed, previous articles describe the depletion of PIP2 in
pre-incubated cells with high concentrations of wortman-
nin.34–44 Interestingly, in our test the toxin still showed an
allosteric effect with capsaicin (n = 6). As a corollary, the
only remaining possibility is a PLA2 involvement. The in-
volvement of this pathway was checked by adding ETYA,
a non-specific inhibitor of cyclooxygenases (COX) and li-
poxygenases (LOX). Both compounds are connected to
the PLA2 pathway (Figure 4). In this test, no effect was vi-
sible confirming the involvement of PLA2 pathway in the
effect of gigantoxin I on TRPV1 channels (n = 3).
Since voltage-gated potassium and sodium channels
are considered as the prime targets of sea anemone pepti-
des, the effect of 1 μM gigantoxin I was also tested on a
large collection of ion channels, including: Kv 1.1, Kv 1.2,
Kv 1.3, Kv 1.4, Kv 1.5, Kv 1.6, ShakerIR, hERG, Nav 1.1,
Nav 1.2, Nav 1.4, Nav 1.5, Nav 1.6, Nav 1.7, Nav 1.8 and
DmNav1. Here, no effect on these subtypes was found
(data not shown), indicating a certain selectivity of gigan-
toxin I.
4. Discussion
Gigantoxin I, the first isolated EGF-like toxin of na-
tural origin, was previously described to have crab toxi-
city with weakly lethal effect. Nevertheless, the physiolo-
gical target of this toxin remained unclear. In this study, an
allosteric effect on TRPV1 channels was shown. Remar-
kably, this effect corresponds with the previously descri-
bed effect of cnidaria venom, indicating that EGF-like to-
xins might be the link between the cnidaria venom and
TRPV1 channels. Because this new information may lead
to the development of new analgesic treatments in cnida-
ria intoxication, it is important to find out the exact action
mechanism of this TRPV1 channel modulating toxin. This
study shows the involvement of the intracellular PLA2 de-
pendent pathway. Keeping in mind that gigantoxin I pos-
sesses 33% homology with the mammalian EFG factor
(see Figure 1), we hypothesize that gigantoxin I acts as an
EGF factor by stimulating a tyrosine kinase activity of the
EGF receptor and thus the calcium-dependent PLA2 acti-
vity. As a consequence, PLA2 releases AA which is oxidi-
zed by LOX generating metabolites such as HPETE
which in turn act as TRPV1 channel agonist. Prostaglan-
dine E2 (PGE2), another AA metabolism product genera-
ted via COX, can act on G-protein coupled receptors
(GPCR), inducing PKA and PKC activity and thus sensi-
tizing TRPV1 channels. Since we ruled out the participa-
tion of PKA or PKC in this study, a role of the PLA2 de-
pendent pathway involving GPCRs is unlikely. Therefore,
we can conclude that PLA2/AA/LOX is most probably the
main pathway that is involved in the gigantoxin I induced
effect on TRPV1 channels. An important remaining que-
stion is why TRPV1 channels first need to be activated be-
fore visible effect is induced by gigantoxin I. It is known
that EGF requires concomitant elevation of intracellular
calcium for PLA2 activity.
45 The same conditions may be
needed for the activation of PLA2 when gigantoxin I is
bound to EGF receptor. Therefore, the opening of TRPV1
channels by an agonist (e.g. capsaicin) inducing inward cal-
cium current might be needed for the activation of the intra-
cellular cascade leading to the described TRPV1 effect.
In conclusion, this study describes the physiological
target of gigantoxin I and the involved intracellular
EGFR/PLA2/AA/LOX pathway in the action mechanism
of the toxin. This is the first time that this pathway is des-
cribed in the indirect activation of TRPV1 channels by to-
xins. This pathway and its coupling to TRPV1 channel ac-
tivation can serve as a model in further research on toxins
and ion channels including the APHC1 toxin mentioned
before. This new knowledge also leads to a better under-
standing of the action mechanism of TRPV1 channels
themselves. Since gigantoxin I is a link between the previ-
ously described painful cnidaria envenomation symptoms
and the effect on TRPV1 channel, these new insights may
lead to the development of new analgesic treatments in
cnidaria intoxications.
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Povzetek
Gigantoksin I, izoliran iz morske vetrnice Stichodactyla gigantea, je prvi toksin naravnega izvora strukturno podoben
epidermalnemu rastnemu faktorju (EGF). V pri~ujo~i raziskavi smo odkrili interakcijo med gigantoksinom I in vani-
loidnim kanal~kom podvrste I s prehodnim receptorskim potencialom (TRPV1). TRPV1 je neselektivni kationski ka-
nal~ek, udele en pri zaznavanju bole~ine in opisan kot farmakolo{ka tar~a knidarijskih strupov. Na{i rezultati odkriva-
jo vpletenost signalne poti EGF receptor/fosfolipaza A2/arahidonska kislina/lipooksigenaza (EGFR/PLA2/AA/LOX) v
posredno aktivacijo kanal~kov TRPV1 z gigantoksinom I. Vpletenost te signalne poti v posredno aktivacijo kanal~kov
TRPV1 z gigantoksinom I je opisana prvi~. Na{i rezultati ne odkrivajo le vpogleda v potencialne u~inke, ki jih lahko
izzove ta nova skupina toksinov, temve~ omogo~ajo tudi bolj{e razumevanje mehanizma delovanja kanal~kov TRPV1
samih.
